Inactive/Delisted stock
Lyell Immunopharma Stock (NASDAQ:LYEL)
Previous Close
$11.46
52W Range
$7.65 - $53.50
50D Avg
$9.07
200D Avg
$16.13
Market Cap
$188.95M
Avg Vol (3M)
$86.93K
Beta
-0.27
Div Yield
-
LYEL Company Profile
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.